Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donati, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donati, F.
Related Collections
Right arrow All Neuropsychology/Behavior
Right arrow All Epilepsy/Seizures
Right arrow Antiepileptic drugs
Right arrow Partial seizures
NEUROLOGY 2006;67:679-682
© 2006 American Academy of Neurology
Brief Communications

Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures

F. Donati, MD, G. Gobbi, MD, J. Campistol, MD, G. Rapatz, MSc, M. Daehler, Y. Sturm, PhD, A. P. Aldenkamp, MD on behalf of The Oxcarbazepine Cognitive Study Group

From Neurologie (F.D.), Spitalzentrum Biel, University Hospital, Bern, Switzerland; Neuropsichiatrica Infantile (G.G.), Ospedale Maggiore, Bologna, Italy; Servicio de Neuropediatria (J.C.), Hospital Sant Joan de Deu, Esplugues, Barcelona, Spain; Novartis Pharma AG (G.R., M.D., Y.S.), Basel, Switzerland; Epilepsie-centrum Kempenhaeghe (A.P.A.), Heeze and Department of Neurology, University of Maastricht, The Netherlands

Address correspondence and reprint requests to: Dr. Albert P. Aldenkamp, Department of Behavioural Sciences, Epilepsy Centre Kempenhaeghe, P.O. Box 61, NL-5590 AB Heeze, The Netherlands; e-mail: aldenkampB{at}kempenhaeghe.nl

The authors investigated the effect of oxcarbazepine on cognitive function in children and adolescents (6 to younger than 17 years of age) with newly diagnosed partial seizures in an open-label comparison with standard antiepileptic drug therapy (carbamazepine and valproate). No differences in cognitive tests were observed between oxcarbazepine and carbamazepine/valproate over a 6-month treatment period.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 22 issue to find the title link for this article.

Supported by Novartis Pharma AG.

Disclosure: Dr. Sturm, Ms. Daehler, and Mr. Rapatz are employees of Novartis Pharma AG. Dr. Sturm and Mr. Rapatz are also stockholders in the company and hold equity in excess of $10,000 in Novartis Pharma AG. Dr. Donati has received an honorarium from Novartis for less than $10,000. Drs. Gobbi, Campistol, and Aldenkamp have nothing to disclose.

Received August 1, 2005. Accepted in final form April 10, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.